SEARCH

SEARCH BY CITATION

References

  • 1
    Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia. Part I. Thromb Haemost 1996; 76: 65162.
  • 2
    Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII–tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 33543.
  • 3
    Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 4536.
  • 4
    Dahm AEA, Andersen TO, Rosendaal FR, Sandset PM. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2005; 3: 6518.
  • 5
    Ariëns RAS, Alberio G, Moia M, Mannucci PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999; 81: 2037.
  • 6
    Amini-Nekoo A, Futers TS, Moia M, Mannucci PM, Grant PJ, Ariëns RAS. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113: 53743.
  • 7
    Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 438792.
  • 8
    Tardy-Poncet B, Tardy B, Laporte S, Mismetti P, Amiral J, Piot M, Reynaud J, Campos L, Decousus HJ. Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis. J Thromb Haemost 2003; 1: 50710.
  • 9
    Ameziane N, Seguin C, Borgel D, Fumeron F, Moatti D, Alhenc-Gelas M, Grandchamp B, Aiach M, Emmerich J, De Prost D. The − 33T>C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations. Thromb Haemost 2002; 88: 1959.
  • 10
    Eitzman DT, Westrick RJ, Bi X, Manning SL, Wilkinson JE, Broze GJ, Ginsburg D. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002; 105: 213942.
  • 11
    Sakata T, Mannami T, Baba S, Kokubo Y, Kario K, Okamoto A, Kumeda K, Ohkura N, Katayama Y, Miyata T, Tomoike H, Kato H. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004; 176: 35560.
  • 12
    Maly M, Vojacek J, Hrabos V, Kvasnicka J, Salaj P, Durdil V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol Res 2003; 52: 71929.
  • 13
    Bilgen D, Sonmez H, Ekmekci H, Ulutin T, Ozturk Z, Kokoglu E, Bayram C, Soner A, Domanic N. The relationship of TFPI, Lp (a), and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem 2005; 38: 926.
  • 14
    Golino P, Ravera A, Ragni M, Cirillo P, Piro O, Chiariello M. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation 2003; 108: 28649.